Sentinel Lymph Node Biopsy & Axillary Dissection
Nodes are sampled to check for regional spread.
- 1–3: Sentinel nodes removed (first-drainage nodes)
- I–III: Axillary levels (anatomic tiers)
- Dye + tracer: Detection method (blue dye / radiotracer)
- 10–25: Full dissection nodes (if SLNB positive)
Why nodes are checked first
Nodes are the first stop for spreading cancer cells.
Sentinel node concept
The sentinel node predicts the rest of the chain.
From biopsy to staging
Pathology result feeds directly into N-stage.
N0 — No Positive Axillary Nodes
No cancer cells found in any sampled node.
- 0: Positive nodes (of nodes sampled)
- ~96%: 5-yr survival (N0) (baseline estimate)
- Minimal: Typical therapy (often endocrine only)
- Rarely: Regional RT needed (breast-only field usual)
What N0 means
Disease appears confined to the primary breast tumor.
Baseline prognosis
N0 carries the best outlook of all N-stages.
Treatment implications
Systemic therapy is guided mainly by tumor biology.
N1 — One To Three Positive Axillary Nodes
A small number of axillary nodes now involved.
- 1–3: Positive nodes (axillary only)
- ~86%: 5-yr survival (N1) (baseline estimate)
- Standard chemo: Typical therapy (plus whole-breast RT)
- Often: Regional RT needed (depends on other factors)
Early regional spread
Cancer has begun moving beyond the breast.
Why intensity rises
More nodes signal more micrometastatic risk.
Common regimen shift
Chemotherapy is added for most N1 patients.
N2/N3 — Extensive Regional Nodal Disease
Four or more nodes, or extra node groups, involved.
- 4+: Positive nodes (or extra groups)
- ~55%: 5-yr survival (N3) (baseline estimate)
- Intensive/maximal: Typical therapy (chemo + extended RT)
- Infraclav./int. mammary: Extra groups (beyond axilla)
Beyond the axilla
Spread reaches infraclavicular or internal mammary nodes.
Higher-risk disease
More node groups implies broader micrometastatic reach.
Escalated treatment
Chemotherapy and radiation fields both expand.
Nodal Burden, Treatment Intensity & Prognosis
More positive nodes mean stronger therapy, lower baseline odds.
- N0–N3: N-stage range (increasing burden)
- 96%→38%: Prognosis spread (model estimate range)
- 4 tiers: Therapy escalation (minimal to maximal)
- Breast→extended: Radiation field growth (with rising N-stage)
Nodal burden drives intensity
Each added positive node nudges therapy stronger.
Micrometastatic risk logic
More nodes suggest disease beyond what is visible.
Putting it together
N-stage is a key input to the whole treatment plan.